Whale Large Capital
  • Politics
  • World News
  • Business
  • Investing
  • Politics
  • World News
  • Business
  • Investing

Whale Large Capital

World News

Drugmakers at fault over toxic cough syrup, Indonesia court finds

by August 23, 2024
August 23, 2024
Drugmakers at fault over toxic cough syrup, Indonesia court finds

An Indonesian court ordered two local companies to pay up to 60 million rupiah ($3,850) to each family whose children died of an acute kidney injury or were seriously injured after consuming toxic cough syrup.

More than 200 children in Indonesia died of the injury and about 120 more survived, some of whom lived with disabilities which led to financial hardships for their parents.

Indonesian courts have cited lax oversight by pharmaceutical companies, including local drugmakers and some suppliers, as well as the country’s food and drugs agency (BPOM), in hearings into the poisonings.

In late 2022, more than 20 families launched a civil suit against the agency, the health ministry, and several companies.

Judges at the Central Jakarta court found a drugmaker and a supplier, Afi Farma and CV Samudera Chemical, at fault in the poisonings, according to a ruling released late on Thursday.

The health ministry and the BPOM were cleared of wrongdoing.

The court ordered the companies to pay the parents who brought the suit compensation of 50 million rupiah for children who died and 60 million rupiah for children who were injured.

Parents had asked for 3.4 billion rupiah for each child that died, and 2.2 billion rupiah for survivors. Indonesia’s 2023 gross domestic product per capita was nearly $5,000, data from the country’s Statistics Bureau shows.

Siti Habiba, the lawyer for the parents, said the families were disappointed by the ruling, as the money was given “as though we were beggars.”

“This breaks a lot of the victims’ hearts,” she said, adding the court ignored the parents’ government oversight concerns by not finding the health ministry and the BPOM at fault.

The court document, posted on its website, did not include reasons for the decision.

Afi Farma’s lawyer Reza Wendra Prayogo told Reuters on Friday the firm was “disappointed” with the civil case ruling and the company was still considering its next legal step.

Last year, a criminal court found East Java-based drugmaker Afi Farma guilty of negligence and jailed officials for not testing the ingredients sent by its supplier.

The syrups contained ethylene glycol (EG), a commonly used chemical in products such as brake fluid and antifreeze. A court document from that criminal case said the EG concentration in the syrups reached as high as 99%, where international standards say only 0.1% of EG is safe for consumption.

The company has repeatedly denied negligence.

Reuters could not immediately contact CV Samudera Chemical, an Indonesian soapmaker, whose toxic ingredient made its way to Afi Farma, according to the court document of the Afi Farma criminal case in 2023.

The World Health Organization said the contaminated medicines had also killed children in Gambia and Uzbekistan in 2022.

This post appeared first on cnn.com
0
FacebookTwitterGoogle +Pinterest
previous post
EURUSD and GBPUSD: GBPUSD remains stable in a bullish trend
next post
Ukraine’s march into Russia exposes Putin’s crisis management problem

You may also like

‘It’s as if an atomic bomb fell on...

December 16, 2024

How Pope Francis addressed the role of women...

April 26, 2025

Deadly ‘terror’ attack hits major defense company in...

October 23, 2024

Woman killed by malfunctioning ottoman bed

October 14, 2024

China sentences former Premier League soccer star to...

December 13, 2024

Fear in Antarctic base as research team member...

March 18, 2025

Israeli fighter jet drops bomb near Israeli community...

April 15, 2025

Even hippos, elephants and monkeys are fleeing bloody...

May 22, 2025

A North Korean defector who struggled in South...

October 3, 2024

Journalists injured by Israeli fire during military raid...

September 4, 2024

    Subscribe today to receive exclusive access to all our retirement secrets and income strategies, including special financial news and updates from our experts. From time to time, our newsletters feature valuable insights and analysis on the latest financial trends. Don't miss out on these exclusive updates – join our subscription to stay informed!


    By opting in you agree to receive emails from us. Your information is secure and your privacy is protected.



    Latest

    • The world’s top nuclear powers have no arsenal limits, here are the countries with nukes

      February 8, 2026
    • Iran’s top diplomat says nation’s power lies in defying pressure: ‘No to the great powers’

      February 8, 2026
    • DAVID MARCUS: In rural Virginia, mixed signals for Trump and the GOP

      February 8, 2026
    • North Korea executed teens for listening to K-pop, watching ‘Squid Game’: report

      February 8, 2026
    • Whispering death: Army’s new M1E3 Abrams tank is a hybrid-drive silent killer

      February 8, 2026
    • Tulsi Gabbard denies wrongdoing over delayed whistleblower complaint referral to Congress members: ‘Baseless’

      February 8, 2026

    Categories

    • Business (846)
    • Investing (661)
    • Politics (7,390)
    • World News (3,213)

    Disclaimer: WhaleLargeCapital.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 whalelargecapital.com | All Rights Reserved